Literature DB >> 20818335

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio.

Inna Kuperstein1, Kerensa Broersen, Iryna Benilova, Jef Rozenski, Wim Jonckheere, Maja Debulpaep, Annelies Vandersteen, Ine Segers-Nolten, Kees Van Der Werf, Vinod Subramaniam, Dries Braeken, Geert Callewaert, Carmen Bartic, Rudi D'Hooge, Ivo Cristiano Martins, Frederic Rousseau, Joost Schymkowitz, Bart De Strooper.   

Abstract

The amyloid peptides Aβ(40) and Aβ(42) of Alzheimer's disease are thought to contribute differentially to the disease process. Although Aβ(42) seems more pathogenic than Aβ(40), the reason for this is not well understood. We show here that small alterations in the Aβ(42):Aβ(40) ratio dramatically affect the biophysical and biological properties of the Aβ mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo. A minor increase in the Aβ(42):Aβ(40) ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these Aβ species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non-toxic intermediates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818335      PMCID: PMC2957213          DOI: 10.1038/emboj.2010.211

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase.

Authors:  Nobuto Kakuda; Satoru Funamoto; Sousuke Yagishita; Mako Takami; Satoko Osawa; Naoshi Dohmae; Yasuo Ihara
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

2.  Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.

Authors:  Mostafa Bentahir; Omar Nyabi; Jan Verhamme; Alexandra Tolia; Katrien Horré; Jens Wiltfang; Hermann Esselmann; Bart De Strooper
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

3.  A specific amyloid-beta protein assembly in the brain impairs memory.

Authors:  Sylvain Lesné; Ming Teng Koh; Linda Kotilinek; Rakez Kayed; Charles G Glabe; Austin Yang; Michela Gallagher; Karen H Ashe
Journal:  Nature       Date:  2006-03-16       Impact factor: 49.962

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology.

Authors:  Runsheng Wang; Baiping Wang; Wanxia He; Hui Zheng
Journal:  J Biol Chem       Date:  2006-03-29       Impact factor: 5.157

6.  Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death.

Authors:  Mark Wogulis; Sarah Wright; Damian Cunningham; Tamie Chilcote; Kyle Powell; Russell E Rydel
Journal:  J Neurosci       Date:  2005-02-02       Impact factor: 6.167

Review 7.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

Authors:  J D Harper; P T Lansbury
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

8.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

9.  Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

Authors:  D M Hartley; D M Walsh; C P Ye; T Diehl; S Vasquez; P M Vassilev; D B Teplow; D J Selkoe
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

10.  Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase.

Authors:  Yue Qi-Takahara; Maho Morishima-Kawashima; Yu Tanimura; Georgia Dolios; Naoko Hirotani; Yuko Horikoshi; Fuyuki Kametani; Masahiro Maeda; Takaomi C Saido; Rong Wang; Yasuo Ihara
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

View more
  191 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

3.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

4.  The effect of Cu(2+) and Zn(2+) on the Aβ42 peptide aggregation and cellular toxicity.

Authors:  Anuj K Sharma; Stephanie T Pavlova; Jaekwang Kim; Jungsu Kim; Liviu M Mirica
Journal:  Metallomics       Date:  2013-11       Impact factor: 4.526

5.  Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice.

Authors:  Götz Heilbronner; Yvonne S Eisele; Franziska Langer; Stephan A Kaeser; Renata Novotny; Amudha Nagarathinam; Andreas Aslund; Per Hammarström; K Peter R Nilsson; Mathias Jucker
Journal:  EMBO Rep       Date:  2013-09-03       Impact factor: 8.807

6.  Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology.

Authors:  Dorothee Abramowski; Sabine Rabe; Ajeet Rijal Upadhaya; Julia Reichwald; Simone Danner; Dieter Staab; Estibaliz Capetillo-Zarate; Haruyasu Yamaguchi; Takaomi C Saido; Karl-Heinz Wiederhold; Dietmar Rudolf Thal; Matthias Staufenbiel
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

Review 7.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

8.  mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent.

Authors:  Khaled S Abd-Elrahman; Alison Hamilton; Awatif Albaker; Stephen S G Ferguson
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-12

Review 9.  Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.

Authors:  Jing Liu; Bin Yang; Jun Ke; Wenjia Li; Wen-Chen Suen
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

10.  Assessing Reproducibility in Amyloid β Research: Impact of Aβ Sources on Experimental Outcomes.

Authors:  Alejandro R Foley; Jevgenij A Raskatov
Journal:  Chembiochem       Date:  2020-05-05       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.